TY - JOUR AU - Wolchok, J. D. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Rutkowski, P. AU - Grob, J. J. AU - Cowey, C. L. PY - 2017 DA - 2017// TI - Overall survival with combined nivolumab and ipilimumab in advanced melanoma JO - N Engl J Med. VL - 377 UR - https://doi.org/10.1056/NEJMoa1709684 DO - 10.1056/NEJMoa1709684 ID - Wolchok2017 ER - TY - JOUR AU - Rini, B. I. AU - Plimack, E. R. AU - Stus, V. AU - Gafanov, R. AU - Hawkins, R. AU - Nosov, D. PY - 2019 DA - 2019// TI - Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma JO - N Engl J Med. VL - 380 UR - https://doi.org/10.1056/NEJMoa1816714 DO - 10.1056/NEJMoa1816714 ID - Rini2019 ER - TY - JOUR AU - Paz-Ares, L. AU - Luft, A. AU - Vicente, D. AU - Tafreshi, A. AU - Gümüş, M. AU - Mazières, J. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer JO - N Engl J Med. VL - 379 UR - https://doi.org/10.1056/NEJMoa1810865 DO - 10.1056/NEJMoa1810865 ID - Paz-Ares2018 ER - TY - JOUR AU - Hoos, A. PY - 2016 DA - 2016// TI - Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations JO - Nat Rev Drug Discov. VL - 15 UR - https://doi.org/10.1038/nrd.2015.35 DO - 10.1038/nrd.2015.35 ID - Hoos2016 ER - TY - JOUR AU - Papaioannou, N. E. AU - Beniata, O. V. AU - Vitsos, P. AU - Tsitsilonis, O. AU - Samara, P. PY - 2016 DA - 2016// TI - Harnessing the immune system to improve cancer therapy JO - Ann Transl Med. VL - 4 UR - https://doi.org/10.21037/atm.2016.04.01 DO - 10.21037/atm.2016.04.01 ID - Papaioannou2016 ER - TY - JOUR AU - Ke, W. AU - Zhang, L. AU - Dai, Y. PY - 2020 DA - 2020// TI - The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs) JO - Thorac Cancer. VL - 11 UR - https://doi.org/10.1111/1759-7714.13341 DO - 10.1111/1759-7714.13341 ID - Ke2020 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - N Engl J Med. VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Friedlander, P. AU - Wood, K. AU - Wassmann, K. AU - Christenfeld, A. M. AU - Bhardwaj, N. AU - Oh, W. K. PY - 2018 DA - 2018// TI - A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab JO - J Immunother Cancer. VL - 6 UR - https://doi.org/10.1186/s40425-018-0408-9 DO - 10.1186/s40425-018-0408-9 ID - Friedlander2018 ER - TY - JOUR AU - Wang, D. Y. AU - Salem, J. E. AU - Cohen, J. V. AU - Chandra, S. AU - Menzer, C. AU - Ye, F. PY - 2018 DA - 2018// TI - Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis JO - JAMA Oncol. VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.3923 DO - 10.1001/jamaoncol.2018.3923 ID - Wang2018 ER - TY - JOUR AU - Elkrief, A. AU - Raichani, L. AU - Richard, C. AU - Messaoudene, M. AU - Belkaid, W. AU - Malo, J. PY - 2019 DA - 2019// TI - Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors JO - Oncoimmunology. VL - 8 UR - https://doi.org/10.1080/2162402X.2019.1568812 DO - 10.1080/2162402X.2019.1568812 ID - Elkrief2019 ER - TY - JOUR AU - Bertrand, A. AU - Kostine, M. AU - Barnetche, T. AU - Truchetet, M. E. AU - Schaeverbeke, T. PY - 2015 DA - 2015// TI - Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis JO - BMC Med. VL - 13 UR - https://doi.org/10.1186/s12916-015-0455-8 DO - 10.1186/s12916-015-0455-8 ID - Bertrand2015 ER - TY - JOUR AU - Maughan, B. L. AU - Bailey, E. AU - Gill, D. M. AU - Agarwal, N. PY - 2017 DA - 2017// TI - Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers JO - Front Oncol. VL - 7 ID - Maughan2017 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. AU - McDermott, D. F. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med. VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Kumar, V. AU - Chaudhary, N. AU - Garg, M. AU - Floudas, C. S. AU - Soni, P. AU - Chandra, A. B. PY - 2017 DA - 2017// TI - Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy JO - Front Pharmacol. VL - 8 UR - https://doi.org/10.3389/fphar.2017.00049 DO - 10.3389/fphar.2017.00049 ID - Kumar2017 ER - TY - JOUR AU - Valpione, S. AU - Pasquali, S. AU - Campana, L. G. AU - Piccin, L. AU - Mocellin, S. AU - Pigozzo, J. PY - 2018 DA - 2018// TI - Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade JO - J Transl Med. VL - 16 UR - https://doi.org/10.1186/s12967-018-1467-x DO - 10.1186/s12967-018-1467-x ID - Valpione2018 ER - TY - JOUR AU - Schwinge, D. AU - Schramm, C. PY - 2019 DA - 2019// TI - Sex-related factors in autoimmune liver diseases JO - Semin Immunopathol. VL - 41 UR - https://doi.org/10.1007/s00281-018-0715-8 DO - 10.1007/s00281-018-0715-8 ID - Schwinge2019 ER - TY - JOUR AU - Khoja, L. AU - Day, D. AU - Wei-Wu Chen, T. AU - Siu, L. L. AU - Hansen, A. R. PY - 2017 DA - 2017// TI - Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review JO - Ann Oncol. VL - 28 UR - https://doi.org/10.1093/annonc/mdx286 DO - 10.1093/annonc/mdx286 ID - Khoja2017 ER - TY - JOUR AU - Abolhassani, A. R. AU - Schuler, G. AU - Kirchberger, M. C. AU - Heinzerling, L. PY - 2019 DA - 2019// TI - C-reactive protein as an early marker of immune-related adverse events JO - J Cancer Res Clin Oncol. VL - 145 UR - https://doi.org/10.1007/s00432-019-03002-1 DO - 10.1007/s00432-019-03002-1 ID - Abolhassani2019 ER - TY - JOUR AU - Okiyama, N. AU - Tanaka, R. PY - 2017 DA - 2017// TI - Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6 JO - Nihon Rinsho Meneki Gakkai Kaishi. VL - 40 UR - https://doi.org/10.2177/jsci.40.95 DO - 10.2177/jsci.40.95 ID - Okiyama2017 ER - TY - JOUR AU - Fujisawa, Y. AU - Yoshino, K. AU - Otsuka, A. AU - Funakoshi, T. AU - Fujimura, T. AU - Yamamoto, Y. PY - 2017 DA - 2017// TI - Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab JO - J Dermatol Sci. VL - 88 UR - https://doi.org/10.1016/j.jdermsci.2017.07.007 DO - 10.1016/j.jdermsci.2017.07.007 ID - Fujisawa2017 ER - TY - JOUR AU - Diehl, A. AU - Yarchoan, M. AU - Hopkins, A. AU - Jaffee, E. AU - Grossman, S. A. PY - 2017 DA - 2017// TI - Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.23217 DO - 10.18632/oncotarget.23217 ID - Diehl2017 ER - TY - JOUR AU - Nakamura, Y. AU - Tanaka, R. AU - Maruyama, H. AU - Ishitsuka, Y. AU - Okiyama, N. AU - Watanabe, R. PY - 2019 DA - 2019// TI - Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies JO - Jpn J Clin Oncol. VL - 49 UR - https://doi.org/10.1093/jjco/hyy201 DO - 10.1093/jjco/hyy201 ID - Nakamura2019 ER - TY - JOUR AU - Khan, S. AU - Khan, S. A. AU - Luo, X. AU - Fattah, F. J. AU - Saltarski, J. AU - Gloria-McCutchen, Y. PY - 2019 DA - 2019// TI - Immune dysregulation in cancer patients developing immune-related adverse events JO - Br J Cancer. VL - 120 UR - https://doi.org/10.1038/s41416-018-0155-1 DO - 10.1038/s41416-018-0155-1 ID - Khan2019 ER - TY - JOUR AU - Lim, S. Y. AU - Lee, J. H. AU - Gide, T. N. AU - Menzies, A. M. AU - Guminski, A. AU - Carlino, M. S. PY - 2019 DA - 2019// TI - Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy JO - Clin Cancer Res. VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-2795 DO - 10.1158/1078-0432.CCR-18-2795 ID - Lim2019 ER - TY - JOUR AU - Bomze, D. AU - Hasan Ali, O. AU - Bate, A. AU - Flatz, L. PY - 2019 DA - 2019// TI - Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden JO - JAMA Oncol. VL - 5 UR - https://doi.org/10.1001/jamaoncol.2019.3221 DO - 10.1001/jamaoncol.2019.3221 ID - Bomze2019 ER - TY - JOUR AU - Pistillo, M. P. AU - Fontana, V. AU - Morabito, A. AU - Dozin, B. AU - Laurent, S. AU - Carosio, R. PY - 2019 DA - 2019// TI - Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study JO - Cancer Immunol Immunother VL - 68 UR - https://doi.org/10.1007/s00262-018-2258-1 DO - 10.1007/s00262-018-2258-1 ID - Pistillo2019 ER - TY - JOUR AU - Chaput, N. AU - Lepage, P. AU - Coutzac, C. AU - Soularue, E. AU - Roux, K. AU - Monot, C. PY - 2017 DA - 2017// TI - Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab JO - Ann Oncol. VL - 28 UR - https://doi.org/10.1093/annonc/mdx108 DO - 10.1093/annonc/mdx108 ID - Chaput2017 ER - TY - JOUR AU - Shahabi, V. AU - Berman, D. AU - Chasalow, S. D. AU - Wang, L. AU - Tsuchihashi, Z. AU - Hu, B. PY - 2013 DA - 2013// TI - Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events JO - J Transl Med. VL - 11 UR - https://doi.org/10.1186/1479-5876-11-75 DO - 10.1186/1479-5876-11-75 ID - Shahabi2013 ER - TY - JOUR AU - Tarhini, A. A. AU - Zahoor, H. AU - Lin, Y. AU - Malhotra, U. AU - Sander, C. AU - Butterfield, L. H. PY - 2015 DA - 2015// TI - Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma JO - J Immunother Cancer. VL - 3 UR - https://doi.org/10.1186/s40425-015-0081-1 DO - 10.1186/s40425-015-0081-1 ID - Tarhini2015 ER - TY - JOUR AU - Hasan Ali, O. AU - Berner, F. AU - Bomze, D. AU - Fässler, M. AU - Diem, S. AU - Cozzio, A. PY - 2019 DA - 2019// TI - Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors JO - Eur J Cancer. VL - 107 UR - https://doi.org/10.1016/j.ejca.2018.11.009 DO - 10.1016/j.ejca.2018.11.009 ID - Hasan Ali2019 ER - TY - JOUR AU - Tahir, S. A. AU - Gao, J. AU - Miura, Y. AU - Blando, J. AU - Tidwell, R. S. S. AU - Zhao, H. PY - 2019 DA - 2019// TI - Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities JO - Proc Natl Acad Sci U S A. VL - 116 UR - https://doi.org/10.1073/pnas.1908079116 DO - 10.1073/pnas.1908079116 ID - Tahir2019 ER - TY - JOUR AU - Toi, Y. AU - Sugawara, S. AU - Sugisaka, J. AU - Ono, H. AU - Kawashima, Y. AU - Aiba, T. PY - 2019 DA - 2019// TI - Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer JO - JAMA Oncol. VL - 5 UR - https://doi.org/10.1001/jamaoncol.2018.5860 DO - 10.1001/jamaoncol.2018.5860 ID - Toi2019 ER - TY - STD TI - Gay S, Rossi G, Corica G, Graziani G, Genova C, Rijavec E, et al. RETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study. Endocrine. 2019; https://doi.org/10.1007/s12020-019-01854-8. ID - ref33 ER - TY - JOUR AU - Johnson, D. AU - Patel, A. B. AU - Uemura, M. I. AU - Trinh, V. A. AU - Jackson, N. AU - Zobniw, C. M. PY - 2019 DA - 2019// TI - IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy JO - Cancer Immunol Res. VL - 7 UR - https://doi.org/10.1158/2326-6066.CIR-18-0682 DO - 10.1158/2326-6066.CIR-18-0682 ID - Johnson2019 ER - TY - JOUR AU - Heppt, M. V. AU - Heinzerling, L. AU - Kähler, K. C. AU - Forschner, A. AU - Kirchberger, M. C. AU - Loquai, C. PY - 2017 DA - 2017// TI - Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition JO - Eur J Cancer (Oxford, England: 1990) VL - 82 UR - https://doi.org/10.1016/j.ejca.2017.05.038 DO - 10.1016/j.ejca.2017.05.038 ID - Heppt2017 ER - TY - JOUR AU - Coussens, L. M. AU - Raymond, W. W. AU - Bergers, G. AU - Laig-Webster, M. AU - Behrendtsen, O. AU - Werb, Z. PY - 1999 DA - 1999// TI - Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis JO - Genes Dev. VL - 13 UR - https://doi.org/10.1101/gad.13.11.1382 DO - 10.1101/gad.13.11.1382 ID - Coussens1999 ER - TY - JOUR AU - Cordon-Cardo, C. AU - Prives, C. PY - 1999 DA - 1999// TI - At the crossroads of inflammation and tumorigenesis JO - J Exp Med. VL - 190 UR - https://doi.org/10.1084/jem.190.10.1367 DO - 10.1084/jem.190.10.1367 ID - Cordon-Cardo1999 ER - TY - JOUR AU - Hudson, J. D. AU - Shoaibi, M. A. AU - Maestro, R. AU - Carnero, A. AU - Hannon, G. J. AU - Beach, D. H. PY - 1999 DA - 1999// TI - A proinflammatory cytokine inhibits p53 tumor suppressor activity JO - J Exp Med. VL - 190 UR - https://doi.org/10.1084/jem.190.10.1375 DO - 10.1084/jem.190.10.1375 ID - Hudson1999 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2000 DA - 2000// TI - The hallmarks of cancer JO - Cell. VL - 100 UR - https://doi.org/10.1016/S0092-8674(00)81683-9 DO - 10.1016/S0092-8674(00)81683-9 ID - Hanahan2000 ER - TY - JOUR AU - Shrotriya, S. AU - Walsh, D. AU - Bennani-Baiti, N. AU - Thomas, S. AU - Lorton, C. PY - 2015 DA - 2015// TI - C-Reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review JO - PloS one. VL - 10 UR - https://doi.org/10.1371/journal.pone.0143080 DO - 10.1371/journal.pone.0143080 ID - Shrotriya2015 ER - TY - JOUR AU - Nakayama, T. AU - Saito, K. AU - Kumagai, J. AU - Nakajima, Y. AU - Kijima, T. AU - Yoshida, S. PY - 2018 DA - 2018// TI - Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma JO - Clin Genitourin Cancer. VL - 16 UR - https://doi.org/10.1016/j.clgc.2018.07.027 DO - 10.1016/j.clgc.2018.07.027 ID - Nakayama2018 ER - TY - JOUR AU - Weber, J. S. AU - Kahler, K. C. AU - Hauschild, A. PY - 2012 DA - 2012// TI - Management of immune-related adverse events and kinetics of response with ipilimumab JO - J Clin Oncol. VL - 30 UR - https://doi.org/10.1200/JCO.2012.41.6750 DO - 10.1200/JCO.2012.41.6750 ID - Weber2012 ER - TY - JOUR AU - Hara, M. AU - Nagasaki, T. AU - Shiga, K. AU - Takahashi, H. AU - Takeyama, H. PY - 2017 DA - 2017// TI - High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab JO - Surg Today. VL - 47 UR - https://doi.org/10.1007/s00595-016-1404-7 DO - 10.1007/s00595-016-1404-7 ID - Hara2017 ER - TY - JOUR AU - Atreya, R. AU - Mudter, J. AU - Finotto, S. AU - Müllberg, J. AU - Jostock, T. AU - Wirtz, S. PY - 2000 DA - 2000// TI - Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo JO - Nat Med. VL - 6 UR - https://doi.org/10.1038/75068 DO - 10.1038/75068 ID - Atreya2000 ER - TY - JOUR AU - Colotta, F. AU - Allavena, P. AU - Sica, A. AU - Garlanda, C. AU - Mantovani, A. PY - 2009 DA - 2009// TI - Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability JO - Carcinogenesis. VL - 30 UR - https://doi.org/10.1093/carcin/bgp127 DO - 10.1093/carcin/bgp127 ID - Colotta2009 ER - TY - JOUR AU - Scheller, J. AU - Chalaris, A. AU - Schmidt-Arras, D. AU - Rose-John, S. PY - 2011 DA - 2011// TI - The pro- and anti-inflammatory properties of the cytokine interleukin-6 JO - Biochim Biophys Acta. VL - 1813 UR - https://doi.org/10.1016/j.bbamcr.2011.01.034 DO - 10.1016/j.bbamcr.2011.01.034 ID - Scheller2011 ER - TY - JOUR AU - Asegaonkar, S. B. AU - Asegaonkar, B. N. AU - Takalkar, U. V. AU - Advani, S. AU - Thorat, A. P. PY - 2015 DA - 2015// TI - C-Reactive protein and breast cancer: new insights from old molecule JO - Int J Breast Cancer. VL - 2015 UR - https://doi.org/10.1155/2015/145647 DO - 10.1155/2015/145647 ID - Asegaonkar2015 ER - TY - JOUR AU - Kumari, N. AU - Dwarakanath, B. S. AU - Das, A. AU - Bhatt, A. N. PY - 2016 DA - 2016// TI - Role of interleukin-6 in cancer progression and therapeutic resistance JO - Tumour Biol VL - 37 UR - https://doi.org/10.1007/s13277-016-5098-7 DO - 10.1007/s13277-016-5098-7 ID - Kumari2016 ER - TY - JOUR AU - Lee, D. W. AU - Gardner, R. AU - Porter, D. L. AU - Louis, C. U. AU - Ahmed, N. AU - Jensen, M. PY - 2014 DA - 2014// TI - Current concepts in the diagnosis and management of cytokine release syndrome JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-05-552729 DO - 10.1182/blood-2014-05-552729 ID - Lee2014 ER - TY - JOUR AU - Brudno, J. N. AU - Kochenderfer, J. N. PY - 2016 DA - 2016// TI - Toxicities of chimeric antigen receptor T cells: recognition and management JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2016-04-703751 DO - 10.1182/blood-2016-04-703751 ID - Brudno2016 ER - TY - JOUR AU - Khoja, L. AU - Atenafu, E. G. AU - Templeton, A. AU - Qye, Y. AU - Chappell, M. A. AU - Saibil, S. PY - 2016 DA - 2016// TI - The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma JO - Cancer Med. VL - 5 UR - https://doi.org/10.1002/cam4.878 DO - 10.1002/cam4.878 ID - Khoja2016 ER - TY - JOUR AU - Rotondi, M. AU - Chiovato, L. AU - Romagnani, S. AU - Serio, M. AU - Romagnani, P. PY - 2007 DA - 2007// TI - Role of chemokines in endocrine autoimmune diseases JO - Endocr Rev. VL - 28 UR - https://doi.org/10.1210/er.2006-0044 DO - 10.1210/er.2006-0044 ID - Rotondi2007 ER - TY - JOUR AU - Tokunaga, R. AU - Zhang, W. AU - Naseem, M. AU - Puccini, A. AU - Berger, M. D. AU - Soni, S. PY - 2018 DA - 2018// TI - CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy JO - Cancer Treat Rev. VL - 63 UR - https://doi.org/10.1016/j.ctrv.2017.11.007 DO - 10.1016/j.ctrv.2017.11.007 ID - Tokunaga2018 ER - TY - JOUR AU - Magliozzi, R. AU - Howell, O. AU - Vora, A. AU - Serafini, B. AU - Nicholas, R. AU - Puopolo, M. PY - 2007 DA - 2007// TI - Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology JO - Brain. VL - 130 ID - Magliozzi2007 ER - TY - JOUR AU - Henneken, M. AU - Dorner, T. AU - Burmester, G. R. AU - Berek, C. PY - 2005 DA - 2005// TI - Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus JO - Arthritis Res Ther. VL - 7 UR - https://doi.org/10.1186/ar1776 DO - 10.1186/ar1776 ID - Henneken2005 ER - TY - JOUR AU - Barone, F. AU - Bombardieri, M. AU - Rosado, M. M. AU - Morgan, P. R. AU - Challacombe, S. J. AU - Vita, S. PY - 2008 DA - 2008// TI - CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization JO - J Immunol. VL - 180 UR - https://doi.org/10.4049/jimmunol.180.7.5130 DO - 10.4049/jimmunol.180.7.5130 ID - Barone2008 ER - TY - JOUR AU - Armengol, M. P. AU - Cardoso-Schmidt, C. B. AU - Fernandez, M. AU - Ferrer, X. AU - Pujol-Borrell, R. AU - Juan, M. PY - 2003 DA - 2003// TI - Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7 B and T lymphocytes in thyroid autoimmune diseases JO - J Immunol. VL - 170 UR - https://doi.org/10.4049/jimmunol.170.12.6320 DO - 10.4049/jimmunol.170.12.6320 ID - Armengol2003 ER - TY - JOUR AU - Rioja, I. AU - Hughes, F. J. AU - Sharp, C. H. AU - Warnock, L. C. AU - Montgomery, D. S. AU - Akil, M. PY - 2008 DA - 2008// TI - Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor JO - Arthritis Rheum. VL - 58 UR - https://doi.org/10.1002/art.23667 DO - 10.1002/art.23667 ID - Rioja2008 ER - TY - JOUR AU - Meraouna, A. AU - Cizeron-Clairac, G. AU - Panse, R. L. AU - Bismuth, J. AU - Truffault, F. AU - Tallaksen, C. PY - 2006 DA - 2006// TI - The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis JO - Blood. VL - 108 UR - https://doi.org/10.1182/blood-2005-06-2383 DO - 10.1182/blood-2005-06-2383 ID - Meraouna2006 ER - TY - JOUR AU - Yamazaki, N. AU - Kiyohara, Y. AU - Uhara, H. AU - Iizuka, H. AU - Uehara, J. AU - Otsuka, F. PY - 2017 DA - 2017// TI - Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma JO - Cancer Sci. VL - 108 UR - https://doi.org/10.1111/cas.13226 DO - 10.1111/cas.13226 ID - Yamazaki2017 ER - TY - JOUR AU - Son, B. AU - Lee, S. AU - Youn, H. AU - Kim, E. AU - Kim, W. AU - Youn, B. PY - 2017 DA - 2017// TI - The role of tumor microenvironment in therapeutic resistance JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.13907 DO - 10.18632/oncotarget.13907 ID - Son2017 ER - TY - JOUR AU - Bertino, G. AU - Demma, S. AU - Ardiri, A. AU - Proiti, M. AU - Mangia, A. AU - Gruttadauria, S. PY - 2015 DA - 2015// TI - The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies JO - Biomed Res Int. VL - 2015 UR - https://doi.org/10.1155/2015/731469 DO - 10.1155/2015/731469 ID - Bertino2015 ER - TY - JOUR AU - Moudgil, K. D. AU - Choubey, D. PY - 2011 DA - 2011// TI - Cytokines in autoimmunity: role in induction, regulation, and treatment JO - J Interferon Cytokine Res. VL - 31 UR - https://doi.org/10.1089/jir.2011.0065 DO - 10.1089/jir.2011.0065 ID - Moudgil2011 ER - TY - JOUR AU - Santamaria, P. PY - 2003 DA - 2003// TI - Cytokines and chemokines in autoimmune disease: an overview JO - Adv Exp Med Biol. VL - 520 UR - https://doi.org/10.1007/978-1-4615-0171-8_1 DO - 10.1007/978-1-4615-0171-8_1 ID - Santamaria2003 ER - TY - JOUR AU - Castle, J. C. AU - Kreiter, S. AU - Diekmann, J. AU - Löwer, M. AU - Roemer, N. AU - Graaf, J. PY - 2012 DA - 2012// TI - Exploiting the mutanome for tumor vaccination JO - Cancer Res. VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3722 DO - 10.1158/0008-5472.CAN-11-3722 ID - Castle2012 ER - TY - JOUR AU - Peggs, K. S. AU - Quezada, S. A. AU - Korman, A. J. AU - Allison, J. P. PY - 2006 DA - 2006// TI - Principles and use of anti-CTLA4 antibody in human cancer immunotherapy JO - Curr Opin Immunol. VL - 18 UR - https://doi.org/10.1016/j.coi.2006.01.011 DO - 10.1016/j.coi.2006.01.011 ID - Peggs2006 ER - TY - JOUR AU - Tarhini, A. A. AU - Edington, H. AU - Butterfield, L. H. AU - Lin, Y. AU - Shuai, Y. AU - Tawbi, H. PY - 2014 DA - 2014// TI - Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab JO - PloS one. VL - 9 UR - https://doi.org/10.1371/journal.pone.0087705 DO - 10.1371/journal.pone.0087705 ID - Tarhini2014 ER - TY - JOUR AU - Roncella, S. AU - Laurent, S. AU - Fontana, V. AU - Ferro, P. AU - Franceschini, M. C. AU - Salvi, S. PY - 2016 DA - 2016// TI - CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor JO - Cancer Immunol Immunother. VL - 65 UR - https://doi.org/10.1007/s00262-016-1844-3 DO - 10.1007/s00262-016-1844-3 ID - Roncella2016 ER - TY - JOUR AU - Salvi, S. AU - Fontana, V. AU - Boccardo, S. AU - Merlo, D. F. AU - Margallo, E. AU - Laurent, S. PY - 2012 DA - 2012// TI - Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer JO - Cancer Immunol Immunother. VL - 61 UR - https://doi.org/10.1007/s00262-012-1211-y DO - 10.1007/s00262-012-1211-y ID - Salvi2012 ER - TY - JOUR AU - Akamatsu, H. AU - Murakami, E. AU - Oyanagi, J. AU - Shibaki, R. AU - Kaki, T. AU - Takase, E. PY - 2020 DA - 2020// TI - Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer JO - Oncologist. VL - 25 UR - https://doi.org/10.1634/theoncologist.2019-0299 DO - 10.1634/theoncologist.2019-0299 ID - Akamatsu2020 ER - TY - JOUR AU - Ward, F. J. AU - Dahal, L. N. AU - Wijesekera, S. K. AU - Abdul-Jawad, S. K. AU - Kaewarpai, T. AU - Xu, H. PY - 2013 DA - 2013// TI - The soluble isoform of CTLA-4 as a regulator of T-cell responses JO - Eur J Immunol. VL - 43 UR - https://doi.org/10.1002/eji.201242529 DO - 10.1002/eji.201242529 ID - Ward2013 ER - TY - JOUR AU - Beck, K. E. AU - Blansfield, J. A. AU - Tran, K. Q. AU - Feldman, A. L. AU - Hughes, M. S. AU - ROYAL, R. E. PY - 2006 DA - 2006// TI - Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 JO - J Clin Oncol. VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.5716 DO - 10.1200/JCO.2005.04.5716 ID - Beck2006 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2015 DA - 2015// TI - Pembrolizumab versus Ipilimumab in Advanced Melanoma JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Powles, T. AU - Eder, J. P. AU - Fine, G. D. AU - Braiteh, F. S. AU - Loriot, Y. AU - Cruz, C. PY - 2014 DA - 2014// TI - MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer JO - Nature. VL - 515 UR - https://doi.org/10.1038/nature13904 DO - 10.1038/nature13904 ID - Powles2014 ER - TY - JOUR AU - Berman, D. AU - Parker, S. M. AU - Siegel, J. AU - Chasalow, S. D. AU - Weber, J. AU - Galbraith, S. PY - 2010 DA - 2010// TI - Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma JO - Cancer Immun. VL - 10 ID - Berman2010 ER - TY - JOUR AU - Michot, J. M. AU - Bigenwald, C. AU - Champiat, S. AU - Collins, M. AU - Carbonnel, F. AU - Postel-Vinay, S. PY - 2016 DA - 2016// TI - Immune-related adverse events with immune checkpoint blockade: a comprehensive review JO - Eur J Cancer VL - 54 UR - https://doi.org/10.1016/j.ejca.2015.11.016 DO - 10.1016/j.ejca.2015.11.016 ID - Michot2016 ER - TY - JOUR AU - Humphries, A. AU - Daud, A. PY - 2018 DA - 2018// TI - The gut microbiota and immune checkpoint inhibitors JO - Hum Vaccin Immunotherapeutics. VL - 14 UR - https://doi.org/10.1080/21645515.2018.1442970 DO - 10.1080/21645515.2018.1442970 ID - Humphries2018 ER - TY - JOUR AU - Dubin, K. AU - Callahan, M. K. AU - Ren, B. AU - Khanin, R. AU - Viale, A. AU - Ling, L. PY - 2016 DA - 2016// TI - Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis JO - Nat Commun. VL - 7 UR - https://doi.org/10.1038/ncomms10391 DO - 10.1038/ncomms10391 ID - Dubin2016 ER - TY - JOUR AU - Serriari, N. E. AU - Eoche, M. AU - Lamotte, L. AU - Lion, J. AU - Fumery, M. AU - Marcelo, P. PY - 2014 DA - 2014// TI - Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases JO - Clin Exp Immunol. VL - 176 UR - https://doi.org/10.1111/cei.12277 DO - 10.1111/cei.12277 ID - Serriari2014 ER - TY - STD TI - Round JL, Mazmanian SK. Inducible Foxp3 þ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci. 2010:12204–9 https://doi.org/10.1073/pnas.0909122107. ID - ref81 ER - TY - JOUR AU - Faith, J. J. AU - Ahern, P. P. AU - Ridaura, V. K. AU - Cheng, J. AU - Gordon, J. I. PY - 2014 DA - 2014// TI - Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice JO - Sci Transl Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008051 DO - 10.1126/scitranslmed.3008051 ID - Faith2014 ER - TY - JOUR AU - Khan, Z. AU - Hammer, C. AU - Guardino, E. AU - Chandler, G. S. AU - Albert, M. L. PY - 2019 DA - 2019// TI - Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach JO - Genome Med. VL - 11 UR - https://doi.org/10.1186/s13073-019-0652-8 DO - 10.1186/s13073-019-0652-8 ID - Khan2019 ER - TY - JOUR AU - Gray-Owen, S. D. AU - Blumberg, R. S. PY - 2006 DA - 2006// TI - CEACAM1: contact-dependent control of immunity JO - Nat Rev Immunol. VL - 6 UR - https://doi.org/10.1038/nri1864 DO - 10.1038/nri1864 ID - Gray-Owen2006 ER - TY - JOUR AU - Skubitz, K. M. AU - Skubitz, A. P. PY - 2011 DA - 2011// TI - Two new synthetic peptides from the N-domain of CEACAM1 (CD66a) stimulate neutrophil adhesion to endothelial cells JO - Biopolymers. VL - 96 UR - https://doi.org/10.1002/bip.21447 DO - 10.1002/bip.21447 ID - Skubitz2011 ER - TY - JOUR AU - Hamid, O. AU - Schmidt, H. AU - Nissan, A. AU - Ridolfi, L. AU - Aamdal, S. AU - Hansson, J. PY - 2011 DA - 2011// TI - A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma JO - J Transl Med. VL - 9 UR - https://doi.org/10.1186/1479-5876-9-204 DO - 10.1186/1479-5876-9-204 ID - Hamid2011 ER - TY - STD TI - Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020; https://doi.org/10.1038/s41571-020-0352-8. ID - ref87 ER - TY - JOUR AU - DuPont, H. L. AU - Ericsson, C. D. AU - Farthing, M. J. AU - Gorbach, S. AU - Pickering, L. K. AU - Rombo, L. PY - 2009 DA - 2009// TI - Expert review of the evidence base for prevention of travelers' diarrhea JO - J Travel Med. VL - 16 UR - https://doi.org/10.1111/j.1708-8305.2008.00299.x DO - 10.1111/j.1708-8305.2008.00299.x ID - DuPont2009 ER - TY - JOUR AU - Castor, M. G. AU - Rezende, B. AU - Resende, C. B. AU - Alessandri, A. L. AU - Fagundes, C. T. AU - Sousa, L. P. PY - 2010 DA - 2010// TI - The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice JO - J Immunol. VL - 184 UR - https://doi.org/10.4049/jimmunol.0902614 DO - 10.4049/jimmunol.0902614 ID - Castor2010 ER - TY - JOUR AU - Song, D. J. AU - Shim, M. H. AU - Lee, N. AU - YOO, Y. AU - CHOUNG, J. T. PY - 2017 DA - 2017// TI - CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis JO - Allergy Asthma Immunol Res. VL - 9 UR - https://doi.org/10.4168/aair.2017.9.4.360 DO - 10.4168/aair.2017.9.4.360 ID - Song2017 ER - TY - JOUR AU - Nardinocchi, L. AU - Sonego, G. AU - Passarelli, F. AU - Avitabile, S. AU - Scarponi, C. AU - Failla, C. M. PY - 2015 DA - 2015// TI - Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer JO - Eur J Immunol. VL - 45 UR - https://doi.org/10.1002/eji.201445052 DO - 10.1002/eji.201445052 ID - Nardinocchi2015 ER - TY - JOUR AU - Nakamura, Y. PY - 2019 DA - 2019// TI - Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events JO - Front Med (Lausanne). VL - 6 UR - https://doi.org/10.3389/fmed.2019.00119 DO - 10.3389/fmed.2019.00119 ID - Nakamura2019 ER - TY - JOUR AU - Abraham, C. AU - Cho, J. PY - 2009 DA - 2009// TI - Interleukin-23/Th17 pathways and inflammatory bowel disease JO - Inflamm Bowel Dis. VL - 15 UR - https://doi.org/10.1002/ibd.20894 DO - 10.1002/ibd.20894 ID - Abraham2009 ER - TY - JOUR AU - Tabchi, S. AU - Messier, C. AU - Blais, N. PY - 2016 DA - 2016// TI - Immune-mediated respiratory adverse events of checkpoint inhibitors JO - Curr Opin Oncol. VL - 28 UR - https://doi.org/10.1097/CCO.0000000000000291 DO - 10.1097/CCO.0000000000000291 ID - Tabchi2016 ER - TY - JOUR AU - Starlets, D. AU - Gore, Y. AU - Binsky, I. AU - Haran, M. AU - Harpaz, N. AU - Shvidel, L. PY - 2006 DA - 2006// TI - Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival JO - Blood. VL - 107 UR - https://doi.org/10.1182/blood-2005-11-4334 DO - 10.1182/blood-2005-11-4334 ID - Starlets2006 ER - TY - JOUR AU - Berner, F. AU - Bomze, D. AU - Diem, S. AU - Ali, O. H. AU - Fässler, M. AU - Ring, S. PY - 2019 DA - 2019// TI - Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer JO - JAMA Oncol. VL - 5 UR - https://doi.org/10.1001/jamaoncol.2019.0402 DO - 10.1001/jamaoncol.2019.0402 ID - Berner2019 ER - TY - JOUR AU - Lambrecht, B. N. AU - Hammad, H. PY - 2015 DA - 2015// TI - The immunology of asthma JO - Nat Immunol. VL - 16 UR - https://doi.org/10.1038/ni.3049 DO - 10.1038/ni.3049 ID - Lambrecht2015 ER - TY - JOUR AU - Bratke, K. AU - Fritz, L. AU - Nokodian, F. AU - Geißler, K. AU - Garbe, K. AU - Lommatzsch, M. PY - 2017 DA - 2017// TI - Differential regulation of PD-1 and its ligands in allergic asthma JO - Clin Exp Allergy. VL - 47 UR - https://doi.org/10.1111/cea.13017 DO - 10.1111/cea.13017 ID - Bratke2017 ER - TY - JOUR AU - Chen, D. S. AU - Irving, B. A. AU - Hodi, F. S. PY - 2012 DA - 2012// TI - Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1 JO - Clin Cancer Res. VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1362 DO - 10.1158/1078-0432.CCR-12-1362 ID - Chen2012 ER - TY - JOUR AU - Werf, N. AU - Redpath, S. A. AU - Azuma, M. AU - Yagita, H. AU - Taylor, M. D. PY - 2013 DA - 2013// TI - Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection JO - PLoS Pathog. VL - 9 UR - https://doi.org/10.1371/journal.ppat.1003215 DO - 10.1371/journal.ppat.1003215 ID - Werf2013 ER - TY - JOUR AU - Zhang, Y. AU - Chung, Y. AU - Bishop, C. AU - Daugherty, B. AU - Chute, H. AU - Holst, P. PY - 2006 DA - 2006// TI - Regulation of T cell activation and tolerance by PDL2 JO - Proc Natl Acad Sci U S A. VL - 103 UR - https://doi.org/10.1073/pnas.0601347103 DO - 10.1073/pnas.0601347103 ID - Zhang2006 ER - TY - JOUR AU - Souza Costa, V. H. AU - Baurakiades, E. AU - Viola Azevedo, M. L. AU - Traiano, G. AU - Kowal Rosales, J. AU - Kunze Larsen, K. S. PY - 2014 DA - 2014// TI - Immunohistochemistry analysis of pulmonary infiltrates in necropsy samples of children with non-pandemic lethal respiratory infections (RSV; ADV; PIV1; PIV2; PIV3; FLU A; FLU B) JO - J Clin Virol. VL - 61 UR - https://doi.org/10.1016/j.jcv.2014.06.026 DO - 10.1016/j.jcv.2014.06.026 ID - Souza Costa2014 ER - TY - JOUR AU - Nishimura, H. AU - Nose, M. AU - Hiai, H. AU - Minato, N. AU - Honjo, T. PY - 1999 DA - 1999// TI - Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor JO - Immunity. VL - 11 UR - https://doi.org/10.1016/S1074-7613(00)80089-8 DO - 10.1016/S1074-7613(00)80089-8 ID - Nishimura1999 ER - TY - JOUR AU - Okazaki, T. AU - Tanaka, Y. AU - Nishio, R. AU - Mitsuiye, T. AU - Mizoguchi, A. AU - Wang, J. PY - 2003 DA - 2003// TI - Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice JO - Nat Med. VL - 9 UR - https://doi.org/10.1038/nm955 DO - 10.1038/nm955 ID - Okazaki2003 ER - TY - JOUR AU - Suzuki, S. AU - Ishikawa, N. AU - Konoeda, F. AU - Seki, N. AU - Fukushima, S. AU - Takahashi, K. PY - 2017 DA - 2017// TI - Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan JO - Neurology. VL - 89 UR - https://doi.org/10.1212/WNL.0000000000004359 DO - 10.1212/WNL.0000000000004359 ID - Suzuki2017 ER - TY - JOUR AU - Williams, T. J. AU - Benavides, D. R. AU - Patrice, K. A. AU - Dalmau, J. O. AU - Ávila, A. L. AU - Le, D. T. PY - 2016 DA - 2016// TI - Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer JO - JAMA Neurol. VL - 73 UR - https://doi.org/10.1001/jamaneurol.2016.1399 DO - 10.1001/jamaneurol.2016.1399 ID - Williams2016 ER - TY - JOUR AU - Scott, E. S. AU - Long, G. V. AU - Guminski, A. AU - Clifton-Bligh, R. J. AU - Menzies, A. M. AU - Tsang, V. H. PY - 2018 DA - 2018// TI - The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma JO - Eur J Endocrinol. VL - 178 UR - https://doi.org/10.1530/EJE-17-0810 DO - 10.1530/EJE-17-0810 ID - Scott2018 ER - TY - JOUR AU - Iglesias, P. PY - 2018 DA - 2018// TI - Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach JO - Eur J Intern Med. VL - 47 UR - https://doi.org/10.1016/j.ejim.2017.08.019 DO - 10.1016/j.ejim.2017.08.019 ID - Iglesias2018 ER - TY - JOUR AU - Delivanis, D. A. AU - Gustafson, M. P. AU - Bornschlegl, S. AU - Merten, M. M. AU - Kottschade, L. AU - Withers, S. PY - 2017 DA - 2017// TI - Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms JO - J Clin Endocrinol Metab. VL - 102 UR - https://doi.org/10.1210/jc.2017-00448 DO - 10.1210/jc.2017-00448 ID - Delivanis2017 ER - TY - JOUR AU - Filette, J. AU - Jansen, Y. AU - Schreuer, M. AU - Everaert, H. AU - Velkeniers, B. AU - Neyns, B. PY - 2016 DA - 2016// TI - Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab JO - J Clin Endocrinol Metab. VL - 101 UR - https://doi.org/10.1210/jc.2016-2300 DO - 10.1210/jc.2016-2300 ID - Filette2016 ER - TY - JOUR AU - Barroso-Sousa, R. AU - Barry, W. T. AU - Garrido-Castro, A. C. AU - Hodi, F. S. AU - Min, L. AU - Krop, I. E. PY - 2018 DA - 2018// TI - Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis JO - JAMA Oncol. VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.3064 DO - 10.1001/jamaoncol.2017.3064 ID - Barroso-Sousa2018 ER - TY - JOUR AU - Raber, W. AU - Gessl, A. AU - Nowotny, P. AU - Vierhapper, H. PY - 2002 DA - 2002// TI - Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects JO - Thyroid. VL - 12 UR - https://doi.org/10.1089/105072502760258712 DO - 10.1089/105072502760258712 ID - Raber2002 ER - TY - JOUR AU - Prummel, M. F. AU - Wiersinga, W. M. PY - 2005 DA - 2005// TI - Thyroid peroxidase autoantibodies in euthyroid subjects JO - Best Pract Res Clin Endocrinol Metab. VL - 19 UR - https://doi.org/10.1016/j.beem.2004.11.003 DO - 10.1016/j.beem.2004.11.003 ID - Prummel2005 ER - TY - JOUR AU - Lupi, I. AU - Zhang, J. AU - Gutenberg, A. AU - Landek-Salgado, M. AU - Tzou, S. C. AU - MORI, S. PY - 2011 DA - 2011// TI - From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis JO - Endocrinology. VL - 152 UR - https://doi.org/10.1210/en.2011-1004 DO - 10.1210/en.2011-1004 ID - Lupi2011 ER - TY - JOUR AU - Gutenberg, A. AU - Buslei, R. AU - Fahlbusch, R. AU - Buchfelder, M. AU - Brück, W. PY - 2005 DA - 2005// TI - Immunopathology of primary hypophysitis: implications for pathogenesis JO - Am J Surg Pathol. VL - 29 UR - https://doi.org/10.1097/01.pas.0000149707.12335.8e DO - 10.1097/01.pas.0000149707.12335.8e ID - Gutenberg2005 ER - TY - JOUR AU - Caturegli, P. PY - 2007 DA - 2007// TI - Autoimmune hypophysitis: an underestimated disease in search of its autoantigen(s) JO - J Clin Endocrinol Metab VL - 92 UR - https://doi.org/10.1210/jc.2007-0808 DO - 10.1210/jc.2007-0808 ID - Caturegli2007 ER - TY - JOUR AU - Faje, A. PY - 2016 DA - 2016// TI - Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights JO - Pituitary. VL - 19 UR - https://doi.org/10.1007/s11102-015-0671-4 DO - 10.1007/s11102-015-0671-4 ID - Faje2016 ER - TY - JOUR AU - Lin, H. H. AU - Gutenberg, A. AU - Chen, T. Y. AU - Tsai, N. M. AU - Lee, C. J. AU - Cheng, Y. C. PY - 2017 DA - 2017// TI - In situ activation of pituitary-infiltrating T lymphocytes in autoimmune hypophysitis JO - Sci Rep. VL - 7 UR - https://doi.org/10.1038/srep43492 DO - 10.1038/srep43492 ID - Lin2017 ER - TY - JOUR AU - Hashimoto, K. AU - Zanger, K. AU - Hollenberg, A. N. AU - Cohen, L. E. AU - Radovick, S. AU - Wondisford, F. E. PY - 2000 DA - 2000// TI - cAMP response element-binding protein-binding protein mediates thyrotropin-releasing hormone signaling on thyrotropin subunit genes JO - J Biol Chem. VL - 275 UR - https://doi.org/10.1074/jbc.M006819200 DO - 10.1074/jbc.M006819200 ID - Hashimoto2000 ER - TY - JOUR AU - Peverelli, E. AU - Mantovani, G. AU - Lania, A. G. AU - Spada, A. PY - 2014 DA - 2014// TI - cAMP in the pituitary: an old messenger for multiple signals JO - J Mol Endocrinol. VL - 52 UR - https://doi.org/10.1530/JME-13-0172 DO - 10.1530/JME-13-0172 ID - Peverelli2014 ER - TY - JOUR AU - Antoni, F. A. AU - Hunter, E. F. AU - Lowry, P. J. AU - Noble, J. M. AU - Seckl, J. R. PY - 1992 DA - 1992// TI - Atriopeptin: an endogenous corticotropin-release inhibiting hormone JO - Endocrinology. VL - 130 ID - Antoni1992 ER - TY - JOUR AU - Kilger, E. AU - Buehler, A. AU - Woelfing, H. AU - Kumar, S. AU - Kaeser, S. A. AU - Nagarathinam, A. PY - 2011 DA - 2011// TI - BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE) JO - J Biol Chem. VL - 286 UR - https://doi.org/10.1074/jbc.M111.288373 DO - 10.1074/jbc.M111.288373 ID - Kilger2011 ER - TY - JOUR AU - Kvistborg, P. AU - Philips, D. AU - Kelderman, S. AU - Hageman, L. AU - Ottensmeier, C. AU - JOSEPH-PIETRAS, D. PY - 2014 DA - 2014// TI - Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response JO - Sci Transl Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008918 DO - 10.1126/scitranslmed.3008918 ID - Kvistborg2014 ER - TY - JOUR AU - Joshi, M. N. AU - Whitelaw, B. C. AU - Palomar, M. T. AU - Wu, Y. AU - Carroll, P. V. PY - 2016 DA - 2016// TI - Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review JO - Clin Endocrinol (Oxf). VL - 85 UR - https://doi.org/10.1111/cen.13063 DO - 10.1111/cen.13063 ID - Joshi2016 ER - TY - JOUR AU - Iwama, S. AU - Remigis, A. AU - Callahan, M. K. AU - Slovin, S. F. AU - Wolchok, J. D. AU - Caturegli, P. PY - 2014 DA - 2014// TI - Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody JO - Sci Transl Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008002 DO - 10.1126/scitranslmed.3008002 ID - Iwama2014 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Schachter, J. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2019 DA - 2019// TI - Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study JO - Lancet Oncol. VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30388-2 DO - 10.1016/S1470-2045(19)30388-2 ID - Robert2019 ER - TY - JOUR AU - Wolchok, J. D. AU - Neyns, B. AU - Linette, G. AU - Negrier, S. AU - Lutzky, J. AU - Thomas, L. PY - 2010 DA - 2010// TI - Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study JO - Lancet Oncol. VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70334-1 DO - 10.1016/S1470-2045(09)70334-1 ID - Wolchok2010 ER - TY - JOUR AU - Weber, J. S. AU - Dummer, R. AU - Pril, V. AU - Lebbe, C. AU - Hodi, F. S. PY - 2013 DA - 2013// TI - Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma JO - Cancer. VL - 119 UR - https://doi.org/10.1002/cncr.27969 DO - 10.1002/cncr.27969 ID - Weber2013 ER - TY - JOUR AU - Brahmer, J. R. AU - Lacchetti, C. AU - Thompson, J. A. PY - 2018 DA - 2018// TI - Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary JO - J Oncol Pract. VL - 14 UR - https://doi.org/10.1200/JOP.18.00005 DO - 10.1200/JOP.18.00005 ID - Brahmer2018 ER - TY - JOUR AU - Gutierrez-Arcelus, M. AU - Rich, S. S. AU - Raychaudhuri, S. PY - 2016 DA - 2016// TI - Autoimmune diseases - connecting risk alleles with molecular traits of the immune system JO - Nat Rev Genet. VL - 17 UR - https://doi.org/10.1038/nrg.2015.33 DO - 10.1038/nrg.2015.33 ID - Gutierrez-Arcelus2016 ER - TY - JOUR AU - Miossec, P. AU - Korn, T. AU - Kuchroo, V. K. PY - 2009 DA - 2009// TI - Interleukin-17 and type 17 helper T cells JO - N Engl J Med. VL - 361 UR - https://doi.org/10.1056/NEJMra0707449 DO - 10.1056/NEJMra0707449 ID - Miossec2009 ER - TY - JOUR AU - Dulos, J. AU - Carven, G. J. AU - Boxtel, S. J. AU - Evers, S. AU - Driessen-Engels, L. J. AU - Hobo, W. PY - 2012 DA - 2012// TI - PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer JO - J Immunother. VL - 35 UR - https://doi.org/10.1097/CJI.0b013e318247a4e7 DO - 10.1097/CJI.0b013e318247a4e7 ID - Dulos2012 ER - TY - JOUR AU - Euw, E. AU - Chodon, T. AU - Attar, N. AU - Jalil, J. AU - Koya, R. C. AU - Comin-Anduix, B. PY - 2009 DA - 2009// TI - CTLA4 blockade increases Th17 cells in patients with metastatic melanoma JO - J Transl Med. VL - 7 UR - https://doi.org/10.1186/1479-5876-7-35 DO - 10.1186/1479-5876-7-35 ID - Euw2009 ER - TY - JOUR AU - Brahmer, J. R. AU - Lacchetti, C. AU - Schneider, B. J. AU - Atkins, M. B. AU - Brassil, K. J. AU - Caterino, J. M. PY - 2018 DA - 2018// TI - Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JO - J Clin Oncol. VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.6385 DO - 10.1200/JCO.2017.77.6385 ID - Brahmer2018 ER - TY - JOUR AU - Long, G. V. AU - Dummer, R. AU - Hamid, O. AU - Gajewski, T. F. AU - Caglevic, C. AU - Dalle, S. PY - 2019 DA - 2019// TI - Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study JO - Lancet Oncol. VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30274-8 DO - 10.1016/S1470-2045(19)30274-8 ID - Long2019 ER - TY - JOUR AU - Mitchell, T. C. AU - Hamid, O. AU - Smith, D. C. AU - Bauer, T. M. AU - Wasser, J. S. AU - Olszanski, A. J. PY - 2018 DA - 2018// TI - Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037) JO - J Clin Oncol. VL - 36 UR - https://doi.org/10.1200/JCO.2018.78.9602 DO - 10.1200/JCO.2018.78.9602 ID - Mitchell2018 ER - TY - STD TI - Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12(2) https://doi.org/10.3390/cancers12020473. ID - ref137 ER - TY - JOUR AU - Wang, L. AU - Wang, H. AU - Chen, H. AU - Wang, W. D. AU - Chen, X. Q. AU - Geng, Q. R. PY - 2015 DA - 2015// TI - Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.5682 DO - 10.18632/oncotarget.5682 ID - Wang2015 ER - TY - JOUR AU - Wei, W. AU - Xu, B. AU - Wang, Y. AU - Wu, C. AU - Jiang, J. AU - Wu, C. PY - 2018 DA - 2018// TI - Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis JO - Medicine. VL - 97 UR - https://doi.org/10.1097/MD.0000000000009617 DO - 10.1097/MD.0000000000009617 ID - Wei2018 ER -